Cover Image
市場調查報告書

幼年特發性關節炎 (PJIA) :開發中產品分析

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361619
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
幼年特發性關節炎 (PJIA) :開發中產品分析 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 84 Pages
簡介

幼年特發性關節炎(PJIA)會影響五個或更多關節。 PJIA會在手指和手的小關節處引起發炎,但負重關節和頜也可能受到影響。症狀包括發燒,粉紅疹,眼睛發炎,關節疼痛,關節腫脹和骨頭發育和生長障礙。治療包括止痛藥,NSAID和改善疾病的抗風濕藥物。

本報告提供幼年特發性關節炎 (PJIA) 的治療藥開發情形調查分析,提供開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

幼年特發性關節炎 (PJIA)的概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

幼年特發性關節炎 (PJIA)的治療藥開發企業

  • Biocon Ltd
  • Coherus BioSciences Inc
  • Livzon Pharmaceutical Group Inc
  • Momenta Pharmaceuticals Inc
  • Mycenax Biotech Inc
  • Oncobiologics Inc
  • Oncodesign SA
  • Panacea Biotec Ltd
  • Regeneron Pharmaceuticals Inc
  • Sandoz International GmbH
  • UCB SA

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9366IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2017, provides an overview of the Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline landscape.

Polyarticular juvenile idiopathic arthritis (PJIA) affects five or more joints. PJIA causes inflammation in small joints of the fingers and hands, but weight-bearing joints and the jaw can also be affected. Symptoms include fevers, pink rash, eye inflammation, joint pain, joint swelling and problems with bone development and growth. Treatment includes painkillers, NSAID and disease-modifying anti-rheumatic drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 2, 1, 2, 9, 2 and 1 respectively.

Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Overview
    • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Companies Involved in Therapeutics Development
    • Biocon Ltd
    • Coherus BioSciences Inc
    • Livzon Pharmaceutical Group Inc
    • Momenta Pharmaceuticals Inc
    • Mycenax Biotech Inc
    • Oncobiologics Inc
    • Oncodesign SA
    • Panacea Biotec Ltd
    • Regeneron Pharmaceuticals Inc
    • Sandoz International GmbH
    • UCB SA
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Drug Profiles
    • abatacept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • certolizumab pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sarilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 02, 2016: Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept)
      • Aug 30, 2016: FDA approves Erelzi, a biosimilar to Enbrel
      • Jul 13, 2016: Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Biocon Ltd, H1 2017
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Coherus BioSciences Inc, H1 2017
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Livzon Pharmaceutical Group Inc, H1 2017
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Momenta Pharmaceuticals Inc, H1 2017
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Mycenax Biotech Inc, H1 2017
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncobiologics Inc, H1 2017
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncodesign SA, H1 2017
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Panacea Biotec Ltd, H1 2017
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Sandoz International GmbH, H1 2017
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by UCB SA, H1 2017
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top